» Articles » PMID: 27905992

Variable Sensitivity to Complement-dependent Cytotoxicity in Murine Models of Neuromyelitis Optica

Overview
Publisher Biomed Central
Date 2016 Dec 2
PMID 27905992
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Studies of neuromyelitis optica (NMO), an autoimmune disease of the central nervous system (CNS), have demonstrated that autoantibodies against the water channel aquaporin-4 (AQP4) induce astrocyte damage through complement-dependent cytotoxicity (CDC). In developing experimental models of NMO using cells, tissues or animals from mice, co-administration of AQP4-IgG and normal human serum, which serves as the source of human complement (HC), is required. The sensitivity of mouse CNS cells to HC and CDC in these models is not known.

Methods: We used HC and recombinant monoclonal antibodies (rAbs) against AQP4 to investigate CDC on mouse neurons, astrocytes, differentiated oligodendrocytes (OLs), and oligodendrocyte progenitors (OPCs) in the context of purified monocultures, neuroglial mixed cultures, and organotypic cerebellar slices.

Results: We found that murine neurons, OLs, and OPCs were sensitive to HC in monocultures. In mixed murine neuroglial cultures, HC-mediated toxicity to neurons and OLs was reduced; however, astrocyte damage induced by an AQP-specific rAb #53 and HC increased neuronal and oligodendroglial loss. OPCs were resistant to HC toxicity in neuroglial mixed cultures. In mouse cerebellar slices, damage to neurons and OLs following rAb #53-mediated CDC was further reduced, but in contrast to neuroglial mixed cultures, astrocyte damage sensitized OPCs to complement damage. Finally, we established that some injury to neurons, OLs, and OPCs in cell and slice cultures resulted from the activation of HC by anti-tissue antibodies to mouse cells.

Conclusions: Murine neurons and oligodendroglia demonstrate variable sensitivity to activated complement based on their differentiation and culture conditions. In organotypic cultures, the protection of neurons, OLs, and OPCs against CDC is eliminated by targeted astrocyte destruction. The activation of human complement proteins on mouse CNS cells necessitates caution when interpreting the results of mouse experimental models of NMO using HC.

Citing Articles

Protein-A immunoadsorption combined with immunosuppressive treatment in refractory primary Sjögren's syndrome coexisting with NMOSD: a case report and literature review.

Fan W, Chen X, Xiao P, Wei B, Zhang Y, Huang J Front Immunol. 2024; 15():1429405.

PMID: 39055718 PMC: 11269126. DOI: 10.3389/fimmu.2024.1429405.


Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination.

Zirngibl M, Assinck P, Sizov A, Caprariello A, Plemel J Mol Neurodegener. 2022; 17(1):34.

PMID: 35526004 PMC: 9077942. DOI: 10.1186/s13024-022-00538-8.


Sera from Patients with NMOSD Reduce the Differentiation Capacity of Precursor Cells in the Central Nervous System.

Gomez-Pinedo U, Garcia-Avila Y, Gallego-Villarejo L, Matias-Guiu J, Benito-Martin M, Esteban-Garcia N Int J Mol Sci. 2021; 22(10).

PMID: 34068922 PMC: 8155872. DOI: 10.3390/ijms22105192.


Experimental Models of Neuroimmunological Disorders: A Review.

da Silva A, Madeira Silva R, Goi L, Molina R, Machado D, Sato D Front Neurol. 2020; 11:389.

PMID: 32477252 PMC: 7235321. DOI: 10.3389/fneur.2020.00389.


Experimental animal models of aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders: progress and shortcomings.

Duan T, Verkman A Brain Pathol. 2019; 30(1):13-25.

PMID: 31587392 PMC: 7034663. DOI: 10.1111/bpa.12793.


References
1.
Papadopoulos M, Bennett J, Verkman A . Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol. 2014; 10(9):493-506. PMC: 4229040. DOI: 10.1038/nrneurol.2014.141. View

2.
Mallon B, Shick H, Kidd G, Macklin W . Proteolipid promoter activity distinguishes two populations of NG2-positive cells throughout neonatal cortical development. J Neurosci. 2002; 22(3):876-85. PMC: 6758537. View

3.
Ricklin D, Lambris J . Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol. 2013; 190(8):3839-47. PMC: 3623010. DOI: 10.4049/jimmunol.1203200. View

4.
Kuroda H, Fujihara K, Takano R, Takai Y, Takahashi T, Misu T . Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J Neuroimmunol. 2012; 254(1-2):178-82. DOI: 10.1016/j.jneuroim.2012.09.002. View

5.
Emery B, Agalliu D, Cahoy J, Watkins T, Dugas J, Mulinyawe S . Myelin gene regulatory factor is a critical transcriptional regulator required for CNS myelination. Cell. 2009; 138(1):172-85. PMC: 2757090. DOI: 10.1016/j.cell.2009.04.031. View